The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young Men
Abstract
The effects of T supplementation on insulin sensitivity, inflammation-sensitive markers, and apolipoproteins remain poorly understood. We do not know whether T's effects on plasma lipids, apolipoproteins, and insulin sensitivity are dose dependent, or whether significant anabolic effects can be achieved at T doses that do not adversely affect these cardiovascular risk factors. To determine the effects of different doses of T, 61 eugonadal men, 18-35 yr of age, were randomly assigned to 1 of 5 groups to receive monthly injections of long-acting GnRH agonist to suppress endogenous T secretion and weekly injections of 25, 50, 125, 300, or 600 mg T enanthate for 20 wk. Dietary energy and protein intakes were standardized. Combined administration of GnRH agonist and graded doses of T enanthate resulted in nadir T concentrations of 253, 306, 542, 1345, and 2370 ng/dl at the 25-, 50-, 125-, 300-, and 600-mg doses, respectively. Plasma high density lipoprotein cholesterol and apolipoprotein A-I concentrations were inversely correlated with total and free T concentrations and were significantly decreased only in the 600 mg/wk group (change in high density lipoprotein cholesterol: -8 +/- 2 mg/dl; P = 0.0005; change in apolipoprotein A-I: -16 +/- 2 mg/dl; P = 0.0001). Serum total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, triglycerides, apolipoprotein B, and apolipoprotein C-III were not significantly correlated with T dose or concentration. There was no significant change in total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, triglycerides, apolipoprotein B, or apolipoprotein C-III levels at any dose. The insulin sensitivity index, glucose effectiveness, and acute insulin response to glucose, derived from the insulin-modified, frequently sampled, iv glucose tolerance test using the Bergman minimal model, did not change significantly at any dose. Circulating levels of C-reactive protein were not correlated with T concentrations and did not change with treatment in any group. Significant increments in fat-free mass, muscle size, and strength were observed at doses that did not affect cardiovascular risk factors. Over a wide range of doses, including those associated with significant gains in fat-free mass and muscle size, T had no adverse effect on insulin sensitivity, plasma lipids, apolipoproteins, or C-reactive protein. Only the highest dose of T (600 mg/wk) was associated with a reduction in plasma high density lipoprotein cholesterol and apolipoprotein A-I. Long-term studies are needed to determine whether T supplementation of older men with low T levels affects atherosclerosis progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 1×
“The indexes for insulin sensitivity (SI), glucose effectiveness (SG), and acute insulin response to glucose (AIRG) were derived from the frequently sampled, iv glucose tolerance test, using the Bergman minimal model (31, 32).”
MethodToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Self-citationKatznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“T replacement of young (8, 9, 12) and older hypogonadal men (5) decreases fat mass.”
BackgroundEffects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Relationships of generalized and regional adiposity to insulin sensitivity in men.
Abate, N., Garg, A., Peshock, R. M., Stray-Gundersen, J., & Grundy, S. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118083 · Cited by 759
Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990) · Metabolism · doi:10.1016/0026-0495(90)90297-p · Cited by 567
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Cited by
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Effects of Androgenic-Anabolic Steroids in Athletes
Hartgens, F., & Kuipers, H. (2004) · Sports Medicine · doi:10.2165/00007256-200434080-00003 · Cited by 873
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Testosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 577
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
Testosterone-mediated immune functions and male life histories
Muehlenbein, M. P., & Bribiescas, R. G. (2005) · American Journal of Human Biology · doi:10.1002/ajhb.20419 · Cited by 448
Sex Differences in Lipid and Lipoprotein Metabolism: It's Not Just about Sex Hormones
Wang, X., Magkos, F., & Mittendorfer, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2061 · Cited by 422
The benefits and risks of testosterone replacement therapy: a review
Morley, J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3025 · Cited by 369
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
Grossmann, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0118 · Cited by 350
Maffei, L., Murata, Y., Rochira, V., Tubert, G., Aranda, C., Vazquez, M., Clyne, C. D., Davis, S., Simpson, E. R., & Carani, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030313 · Cited by 342
Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects
Elbers, J. M. H., Giltay, E. J., Teerlink, T., Scheffer, P. G., Asscheman, H., Seidell, J. C., & Gooren, L. J. G. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01753.x · Cited by 319
Androgens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Tajar, A., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Bartfai, G., Boonen, S., Casanueva, F. F. F., Forti, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2513 · Cited by 318
Association of Bioavailable, Free, and Total Testosterone With Insulin Resistance
Tsai, E. C., Matsumoto, A. M., Fujimoto, W. Y., & Boyko, E. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.861 · Cited by 307
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
Rao, P. M., Kelly, D. M., & Jones, T. H. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.122 · Cited by 292
Adverse health effects of anabolic–androgenic steroids
van Amsterdam, J., Opperhuizen, A., & Hartgens, F. (2010) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2010.02.001 · Cited by 286
Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0454 · Cited by 220
Hypogonadism and male obesity: Focus on unresolved questions
Grossmann, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13723 · Cited by 164
Liu, P. Y., Swerdloff, R. S., & Veldhuis, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0807 · Cited by 143
Grossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12664 · Cited by 139
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Testosterone and type 2 diabetes
Grossmann, M., Gianatti, E. J., & Zajac, J. D. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833919cf · Cited by 108
Sex Hormone-Binding Globulin as an Independent Predictor of Incident Type 2 Diabetes Mellitus in Men
Lakshman, K. M., Bhasin, S., & Araujo, A. B. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq002 · Cited by 100
Self-citationTestosterone replacement therapy: for whom, when and how?
Tsametis, C. P., & Isidori, A. M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.007 · Cited by 96
Vascular Reactivity in Hypogonadal Men Is Reduced by Androgen Substitution
Zitzmann, M., Brune, M., & Nieschlag, E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020504 · Cited by 86
Woodhouse, L. J., Reisz-Porszasz, S., Javanbakht, M., Storer, T. W., Lee, M., Zerounian, H., & Bhasin, S. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00536.2002 · Cited by 73
Self-citationBody composition, metabolic syndrome and testosterone in ageing men
Allan, C. A., Strauss, B. J. G., & McLachlan, R. I. (2007) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901552 · Cited by 67
Salehzadeh, F., Rune, A., Osler, M., & Al-Khalili, L. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0497 · Cited by 66
McCullough, D., Webb, R., Enright, K. J., Lane, K. E., McVeigh, J., Stewart, C. E., & Davies, I. G. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09616-y · Cited by 62
“In contrast, increasing doses of testosterone (25–600 mg/wk) for 20 weeks had no significant effect on insulin sensitivity in resistance-trained males [93].”
BackgroundLate-Life Onset Hypogonadism: A Review
Bassil, N., & Morley, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2010.02.003 · Cited by 59
Hypogonadotropic Hypogonadism in Men with Type 2 Diabetes
Dandona, P., Dhindsa, S., Chandel, A., & Chaudhuri, A. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2001 · Cited by 47
Androgens, Obesity, and Sleep-Disordered Breathing in Men
Liu, P. Y., Caterson, I. D., Grunstein, R. R., & Handelsman, D. J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.002 · Cited by 43
Cakir, E., Ozcan, O., Yaman, H., Akgul, E. O., Bilgi, C., Erbil, M. K., & Yesilova, Z. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2045 · Cited by 28
Metadata
- Authors
- Singh, A. B.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-01-01
- Volume
- 87
- Issue
- 1
- Pages
- 136-143
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2061259561
- Cited by
- 226
- References
- 16
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.